22MA082N ACT: Metabolic Reprograming of Adoptively Transferred T Cells to Potentiate Antitumor Response | Moffitt

Home
Research Science
Academic and Industry Partnerships
Office of Innovation
Available Technologies
Immunotherapies
22MA082N ACT: Metabolic Reprograming of Adoptively Transferred T Cells to Potentiate Antitumor Response

FOR MORE INFORMATION ON THIS TECHNOLOGY, PLEASE CONTACT OUR OFFICE

The Innovation Office
InnovationMarketing@Moffitt.org
(813) 745-6828